All In Biotech

Drug Trial Radar · NCT07481734

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Feb 14, 2027

Study completion Feb 17, 2028

Sponsor

Lead sponsor
Hudson BiotechIndustry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.

Conditions

  • Metabolic Associated Steatotic Liver Disease
  • Nonalcoholic Steatohepatitis
  • Hepatic Steatosis

Interventions

  • TesamorelinDrug

    for injection, 2 mg SC once daily; participant self-administration after training. Dose may be reduced to 1 mg daily if IGF-1 z-score meets protocol threshold.

  • PlaceboDrug

    for injection (mannitol-based, identical appearance), SC once daily.

  • Standardized lifestyle counselingBehavioral

    dietary guidance and physical activity recommendations,delivered at baseline and reinforced at each visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points)Time frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.